Levocetirizine
- Generic Name
- Levocetirizine
- Brand Names
- Xyzal
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 130018-77-8
- Unique Ingredient Identifier
- 6U5EA9RT2O
- Background
Levocetirizine is a selective histamine H antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H receptor than cetirizine.
Levocetirizine was granted FDA approval in 1995.
- Indication
Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It is also used over the counter for a variety of mild allergy symptoms.
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving
- Conditions
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Utrecht Institute for Pharmaceutical Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01496911
- Locations
- 🇳🇱
Royal Netherlands Navy, Den Helder, Noord Holland, Netherlands
A Drug Interaction Study of Montelukast and Levocetirizine
- Conditions
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 30
- Registration Number
- NCT01491503
- Locations
- 🇰🇷
Samsung medical center, Seoul, Korea, Republic of
Drug Use Investigation for XYZAL®
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10728
- Registration Number
- NCT01445262
Omnaris Versus Levocetirizine Phase 4 Study
- Conditions
- Interventions
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 349
- Registration Number
- NCT01430260
- Locations
- 🇰🇷
handok pharmaceuticals co. LTD, Seoul, Korea, Republic of
Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses
- Conditions
- Interventions
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2013-07-17
- Lead Sponsor
- Association Asthma, Bulgaria
- Target Recruit Count
- 24
- Registration Number
- NCT01250652
- Locations
- 🇧🇬
Medical University Sofia, Department of Allergology, Sofia, Bulgaria
3-D Visualization of the Anti-Obstructive Effect of Levocetirizine
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2011-06-22
- Lead Sponsor
- Clinical Research International Limited
- Target Recruit Count
- 1
- Registration Number
- NCT01000792
- Locations
- 🇩🇪
HNO-Praxis Dr. Pasch/Prof. Schlöndorff, Aachen, NRW, Germany
Is Levocetirizine Less Sedating Than Cetirizine?
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 30
- Registration Number
- NCT00826943
- Locations
- 🇺🇸
Vanderbilt University Asthma, Sinus, and Allergy Clinic, Nashville, Tennessee, United States
The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 81
- Registration Number
- NCT00789152
To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Brian J Lipworth
- Target Recruit Count
- 25
- Registration Number
- NCT00679250
- Locations
- 🇬🇧
Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Angus, United Kingdom
🇬🇧Perth Royal Infirmary, Perth, Perthshire, United Kingdom
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 580
- Registration Number
- NCT00653224
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.